How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Wong, Gloria ^a   Sime, Fekade Bruck ^b,c   Lipman, Jeffrey ^a,d   Roberts, Jason A ^a,b,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c QUEEN ELIZABETH HOSPITAL   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Antibiotic; Pharmacodynamics; Pharmacokinetics; TDM

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; QUINOLONE DERIVATIVE; TOBRAMYCIN; VANCOMYCIN;

AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MONITORING; DRUG SAFETY; HUMAN; INFECTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OTOTOXICITY; RENAL CLEARANCE; REVIEW;

EID: 84928237667     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-288     Document Type: Review

References (163)

1. Bellomo R: Mortality in severe sepsis: an inconvenient truth. Crit Care Resusc 2010, 12(1):6-8.
2. Boussekey N, Cantrel J, Dorchin Debrabant L, Langlois J, Devos P, Meybeck A, Chiche A, Georges H, Leroy O: Epidemiology, prognosis, and evolution of management of septic shock in a French intensive care unit: a five years survey. Crit Care Res Pract 2010, 2010:436427.
3. Melamed A, Sorvillo FJ: The burden of sepsis-associated mortality in the United States from 1999 to 2005: an analysis of multiple-cause-of-death data. Crit Care 2009, 13(1):R28.
4. Vincent J-L, Rello J, Marchall JC, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall CD, Sakr Y, Reinhart K: International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302(21):2323-2329.
5. Roberts J, Abdul Aziz M, Lipman J, Mouton J, Vinks A, Felton T, Hope W, Farkas A, Neely M, Schentag J, Drusano G, Frey OR, Theuretzbacher U, Kuti JL, on behalf of The International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases: Individualised antibiotic dosing for patients who are critically ill challenges and potential solutions. Lancet Inf Dis 2014, 14(6):498-509.
6. Taccone FS, Laterre P-F, Dugernier T, Spapen H, Delattre IK, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent J-L, Jacobs F: Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010, 14(4):R126.
7. Roberts JA, Paul SK, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J, DALI Study: DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 2014, 58(8):1072-1083.
8. Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H: Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008, 30(6):674-681.
9. Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J: Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 2011, 55(6):2704-2709.
10. van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY, Schouten MA, Girbes AR: Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care 2008, 23(3):422-430.
11. Swoboda S, Ober MC, Lichtenstern C, Saleh S, Schwenger V, Sonntag HG, Haefeli WE, Hempel G, Hoppe-Tichy T, Weigand MA: Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 2010, 66(3):291-298.
12. Taccone FS, Cotton F, Roisin S, Vincent J-L, Jacobs F: Optimal meropenem concentrations to treat multidrug-resistant pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 2012, 56(4):2129-2131.
13. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW: Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother 2010, 54(9):3717-3722.
14. Wegner C, Hubner NO, Gleich S, Thalmaier U, Kruger CM, Kramer A: One-day point prevalence of emerging bacterial pathogens in a nationwide sample of 62 German hospitals in 2012 and comparison with the results of the one-day point prevalence of 2010. GMS Hyg Infect Control 2013, 8(1):Doc12.
15. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34(6):1589-1596.
16. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP: Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009, 49(3):325-327.
17. Kullar R, Davis SL, Levine DP, Rybak MJ: Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011, 52(8):975-981.
18. McKinnon PS, Paladino JA, Schentag JJ: Evaluation of Area Under the Inhibitory Curve (AUIC) and Time Above the Minimum Inhibitory Concentration (T >MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008, 31(4):345-351.
19. van Lent-Evers NA, Mathôt RA, Geus WP, van Hout BA, Vinks AA: Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 1999, 21(1):63-73.
20. Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R: The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998, 27(1):23-27.
21. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ: Pharmacodynamics of intravenous ciprofloxacin in seriously Ill patients. Antimicrob Agents Chemother 1993, 37(5):1073-1081.
22. Wong G, Brinkman A, Benefield RJ, Carlier M, De Waele JJ, El Helali N, Frey O, Harbarth S, Huttner A, McWhinney B, Misset B, Pea F, Preisenberger J, Roberts MS, Robertson TA, Roehr A, Sime FB, Taccone FS, Ungerer JP, Lipman J, Roberts JA: An international, multicentre survey of beta-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother 2014, 69(5):1416-1423.
23. Roberts JA, Norris R, Paterson DL, Martin JH: Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 2012, 73(1):27-36.
24. Dong H, Wang X, Dong Y, Lei J, Li H, You H, Wang M, Xing J, Sun J, Zhu H: Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents 2011, 38(4):296-300.
25. Udy AA, Roberts JA, De Waele JJ, Paterson DL, Lipman J: What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents 2012, 39(6):455-457.
26. Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney B, Ungerer J, Lipman J, Roberts JA: Sub-therapeutic initial β-lactam concentrations in select critically ill patients. Chest 2012, 142(1):30-39.
27. Kielstein JT, Burkhardt O: Dosing of antibiotics in critically ill patients undergoing renal replacement therapy. Curr Pharm Biotechnol 2011, 12(12):2015-2019.
28. Jamal J-A, Economou CJP, Lipman J, Roberts JA: Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation. Curr Opin Crit Care 2012, 18(5):460-471.
29. Shekar K, Fraser JF, Smith MT, Roberts JA: Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care 2012, 27:741. e749-e718.
30. Choi GYS, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J: Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009, 37:2268-2282.
31. Tam VH, Gamez EA, Weston JS, Gerard LN, Larocco MT, Caeiro JP, Gentry LO, Garey KW: Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 2008, 46(6):862-867.
32. Weisenberg SA, Morgan DJ, Espinal-Witter R, Larone DH: Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem. Diagn Microbiol Infect Dis 2009, 64(2):233-235.
33. Bhat SV, Peleg AY, Lodise TPJ, Shutt KA, Capitano B, Potoski BA, Paterson DL: Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother 2007, 51(12):4390-4395.
34. Vading M, Samuelsen O, Haldorsen B, Sundsfjord AS, Giske CG: Comparison of disk diffusion, Etest and VITEK2 for detection of carbapenemaseproducing Klebsiella pneumoniae with the EUCAST and CLSI breakpoint systems. Clin Microbiol Infect 2011, 17(5):668-674.
35. Kitzis M: Antibiotic assay. In Antibiogram. 3rd edition. Edited by Courvalin P, Leclercq R, Rice LB. Portland, Oregon: ESKA Publishing, ASM Press; 2010:75-88.
36. Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA: Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review. Ann Intensive Care 2012, 2(1):35.
37. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL: Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002, 50(3):425-428.
38. Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J: Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010, 36:332-339.
39. Pea F, Viale P, Cojutti P, Furlanut M: Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach. Antimicrob Agents Chemother 2012, 56(12):6343-6348.
40. Roberts JA, Kirkpatrick CMJ, Roberts MS, Dalley AJ, Lipman J: First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010, 35(2):156-163.
41. Lee GC, Liou H, Yee R, Quan CF, Neldner K: Outcomes of extendedinfusion piperacillin-tazobactam: a retrospective analysis of critically ill patients. Clin Ther 2012, 34(12):2297-2300.
42. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Starr T, Udy AA, Paul SK, Lipman J, Australian and New Zealand Intensive Care Society Clinical Trials Group, Australasian Society for Infectious Diseases Clinical Research Network: A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent betalactam dosing in critically ill patients with severe sepsis: the BLING II study. Crit Care Resusc 2013, 15(3):179-185.
43. Pea F, Cojutti P, Sbrojavacca R, Cadeo B, Cristini F, Bulfoni A, Furlanut M: TDM-guided therapy with daptomycin and meropenem in a morbidly obese. Critically ill patient. Ann Pharmacother 2011, 45:e37.
44. Lamoth F, Buclin T, Pascual A, Vora S, Bolay S, Decosterd LA, Calandra T, Marchetti O: High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother 2010, 54(10):4360-4367.
45. Lonsdale DO, Udy AA, Roberts JA, Lipman J: Antibacterial therapeutic drug monitoring in cerebrospinal fluid: difficulty in achieving adequate drug concentrations. J Neurosurg 2013, 118(2):297-301.
46. Chapuis TM, Giannoni E, Majcherczyk PA, Chiolero R, Schaller M-D, Berger MM, Bolay S, Decosterd LA, Bugnon D, Moreillon P: Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care 2010, 14(2):R51.
47. Simon N, Dussol B, Sampol E, Purgus R, Brunet P, Lacarelle B, Berland Y, Bruguerolle B, Urien S: Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients. Clin Pharmacokinet 2006, 45(5):493-501.
48. Seyler L, Cotton F, Taccone FS, De Backer D, Macours P, Vincent J-L, Jacobs F: Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 2011, 15:R137.
49. Carlier M, Stove V, Roberts JA, Van de Velde E, De Waele JJ, Verstraete AG: Quantification of seven beta-lactam antibiotics and two beta-lactamase inhibitors in human plasma using a validated UPLC-MS/MS method. Int J Antimicrob Agents 2012, 40(5):416-422.
50. Ohmori T, Suzuki A, Niwa T, Ushikoshi H, Shirai K, Yoshida S, Ogura S, Itoh Y: Simultaneous determination of eight beta-lactam antibiotics in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 879:1038-1042.
51. Mendez AS, Steppe M, Schapoval EE: Validation of HPLC and UV spectrophotometric methods for the determination of meropenem in pharmaceutical dosage form. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 33:947-954.
52. McWhinney B, Wallis SC, Hillister T, Roberts JA, Lipman J, Ungerer J: Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878:2036-2043.
53. Briscoe S, McWhinney B, Lipman J, Roberts JA, Ungerer JP: A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2012, 907:178-184.
54. Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, Roberts JA: Protein binding of beta-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother 2013, 57(12):6165-6170.
55. Farkas A, Daroczi G: Individually Designed Optimum Dosing Strategies (ID-ODS): A Multi-Model Based Online Application to Individualize Antibiotic Dosing in Critically Ill Patients. In Proceedings of NewYork-Presbyterian Healthcare System Quality Symposium. Edited by Osten WM, Lazar EJ, Regan BK. New York: The NewYork-Presbyterian; 2013:240.
56. Barclay ML, Kirkpatrick CM, Begg EJ: Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet 1999, 36(2):89-98.
57. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R: Experience with a once-daily aminoglycoside program administered to 2, 184 adult patients. Antimicrob Agents Chemother 1995, 39(3):650-655.
58. Bartal C, Danon A, Schlaeffer F, Reisenberg K, Alkan M, Smoliakov R, Sidi A, Almog Y: Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med 2003, 114(3):194-198.
59. Streetman DS, Nafziger AN, Destache CJ, Bertino AS Jr: Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. Pharmacotherapy 2001, 21(4):443-451.
60. Sanchez-Alcaraz A, Vargas A, Quintana MB, Rocher A, Querol JM, Poveda JL, Hermenegildo M: Therapeutic drug monitoring of tobramycin: once-daily versus twice-daily dosage schedules. J Clin Pharm Ther 1998, 23(5):367-373.
61. Conil JM, Georges B, Ruiz S, Rival T, Seguin T, Cougot P, Fourcade O, Pharmd GH, Saivin S: Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. Br J Clin Pharmacol 2011, 71(1):61-71.
62. Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B, De Backer D, Wittebole X, Wallemacq P, Vincent JL, Jacobs F: Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010, 14(2):R53.
63. Conil JM, Georges B, Breden A, Segonds C, Lavit M, Seguin T, Coley N, Samii K, Chabanon G, Houin G, Saivin S: Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. Int J Antimicrob Agents 2006, 28(3):226-230.
64. Bracco D, Landry C, Dubois MJ, Eggimann P: Pharmacokinetic variability of extended interval tobramycin in burn patients. Burns 2008, 34(6):791-796.
65. Petejova N, Zahalkova J, Duricova J, Kacirova I, Brozmanova H, Urbanek K, Grundmann M, Martinek A: Gentamicin pharmacokinetics during continuous venovenous hemofiltration in critically ill septic patients. J Chemother 2012, 24(2):107-112.
66. Boyer A, Gruson D, Bouchet S, Clouzeau B, Hoang-Nam B, Vargas F, Gilles H, Molimard M, Rogues AM, Moore N: Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk. Drug Saf 2013, 36(4):217-230.
67. Mueller EW, Boucher BA: The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients. Surg Infect (Larchmt) 2009, 10(6):563-570.
68. Prins JM, Weverling GJ, de Blok K, van Ketel RJ, Speelman P: Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother 1996, 40(11):2494-2499.
69. Wallace AW, Jones M, Bertino JS Jr: Evaluation of four once-daily aminoglycoside dosing nomograms. Pharmacotherapy 2002, 22(9):1077-1083.
70. Botha FJ, van der Bijl P, Seifart HI, Parkin DP: Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient. Intensive Care Med 1996, 22(5):443-446.
71. Begg EJ, Barclay ML, Duffull SB: A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995, 39(6):605-609.
72. Fonge H, Kaale E, Govaerts C, Desmet K, Van Schepdael A, Hoogmartens J: Bioanalysis of tobramycin for therapeutic drug monitoring by solidphase extraction and capillary zone electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci 2004, 810(2):313-318.
73. Dasgupta A: Advances in antibiotic measurement. Adv Clin Chem 2012, 56:75-104.
74. Avent ML, Teoh J, Lees J, Eckert KA, Kirkpatrick CM: Comparing 3 methods of monitoring gentamicin concentrations in patients with febrile neutropenia. Ther Drug Monit 2011, 33(5):592-601.
75. Delattre IK, Musuamba FT, Nyberg J, Taccone FS, Laterre PF, Verbeeck RK, Jacobs F, Wallemacq PE: Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients. Ther Drug Monit 2010, 32(6):749-756.
76. Turnidge J: Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin 2003, 17(3):503-528.
77. Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A: Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother 2011, 55(7):3278-3283.
78. Prabaker KK, Tran TP, Pratummas T, Goetz MB, Graber CJ: Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans. J Hosp Med 2012, 7(2):91-97.
79. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A: High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006, 166(19):2138-2144.
80. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH: A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007, 29(6):1107-1115.
81. Lodise TP, Lomaestro B, Graves J, Drusano GL: Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008, 52(4):1330-1336.
82. Bosso JA, Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J, Mauldin PD: Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother 2011, 55(12):5475-5479.
83. Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB: Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity. Am J Med 2010, 123(12):1143-1149.
84. Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME: Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 2010, 9(1):9-14.
85. van Hal SJ, Paterson DL, Lodise TP: Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013, 57(2):734-744.
86. Forouzesh A, Moise PA, Sakoulas G: Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother 2009, 53 (2):483-486.
87. Shields RK, Martello JL, Potoski BA: Is vancomycin ototoxicity a significant risk? Antimicrob Agents Chemother 2009, 53(10):4572. author reply 4572-4573.
88. Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST, Kollef MH: Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006, 130(4):947-955.
89. Iwamoto T, Kagawa Y, Kojima M: Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull 2003, 26(6):876-879.
90. Cheong JY, Makmor-Bakry M, Lau CL, Abdul Rahman R: The relationship between trough concentration of vancomycin and effect on methicillin-resistant Staphylococcus aureus in critically ill patients. S Afr Med J 2012, 102(7):616-619.
91. Ye ZK, Tang HL, Zhai SD: Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. PLoS One 2013, 8(10):e77169.
92. Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM: Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 2006, 57(4):699-704.
93. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, Grabsch EA, Roberts SA, Robson J, Read K, Bak N, Hurley J, Johnson PD, Morris AJ, Mayall BC, Grayson ML: Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004, 38(4):521-528.
94. Moellering RC Jr: Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis 1994, 18(4):544-546.
95. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP: Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009, 66(1):82-98.
96. Potoski BA, Paterson DL: Appropriate pharmacokinetic index for outcome in Staphylococcus aureus pneumonia. Chest 2007, 132(3):1101-1102. author reply 1102-1103.
97. Morrison AP, Melanson SE, Carty MG, Bates DW, Szumita PM, Tanasijevic MJ: What proportion of vancomycin trough levels are drawn too early? Frequency and impact on clinical actions. Am J Clin Pathol 2012, 137(3):472-478.
98. Takahashi Y, Takesue Y, Takubo S, Ishihara M, Nakajima K, Tsuchida T, Ikeuchi H, Uchino M: Preferable timing of therapeutic drug monitoring in patients with impaired renal function treated with once-daily administration of vancomycin. J Infect Chemother 2013, 19(4):709-716.
99. Tobin CM, Darville JM, Thomson AH, Sweeney G, Wilson JF, MacGowan AP, White LO: Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for antibiotic assays questionnaire. J Antimicrob Chemother 2002, 50(5):713-718.
100. Matsumoto K, Takesue Y, Ohmagari N, Mochizuki T, Mikamo H, Seki M, Takakura S, Tokimatsu I, Takahashi Y, Kasahara K, Okada K, Igarashi M, Kobayashi M, Hamada Y, Kimura M, Nishi Y, Tanigawara Y, Kimura T: Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother 2013, 19(3):365-380.
101. Wilson JF, Davis AC, Tobin CM: Evaluation of commercial assays for vancomycin and aminoglycosides in serum: a comparison of accuracy and precision based on external quality assessment. J Antimicrob Chemother 2003, 52(1):78-82.
102. Murphy JE, Gillespie DE, Bateman CV: Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. Am J Health Syst Pharm 2006, 63(23):2365-2370.
103. DeRyke CA, Alexander DP: Optimizing vancomycin dosing through pharmacodynamic assessment targeting area under the concentrationtime curve/minimum inhibitory concentration. Hosp Pharm 2009, 44(9):751-765.
104. Pea F, Bertolissi M, Di Silvestre A, Poz D, Giordano F, Furlanut M: TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients. Int J Antimicrob Agents 2002, 20(5):326-332.
105. Avent ML, Vaska VL, Rogers BA, Cheng AC, van Hal SJ, Holmes NE, Howden BP, Paterson DL: Vancomycin therapeutics and monitoring: a contemporary approach. Intern Med J 2013, 43(2):110-119.
106. Man SS, Carr RR, Ensom MH: Comparison of continuous and intermittent IV infusion of vancomycin: systematic review. Can J Hosp Pharm 2010, 63(5):373-381.
107. James JK, Palmer SM, Levine DP, Rybak MJ: Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 1996, 40(3):696-700.
108. Wysocki M, Delatour F, Faurisson F, Rauss A, Pean Y, Misset B, Thomas F, Timsit JF, Similowski T, Mentec H, Mier L, Dreyfuss D: Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001, 45(9):2460-2467.
109. DiMondi VP, Rafferty K: Review of continuous-infusion vancomycin. Ann Pharmacother 2013, 47(2):219-227.
110. Panday PN, Sturkenboom M: Continuous infusion of vancomycin less effective and safe than intermittent infusion, based on pharmacodynamic and pharmacokinetic principles. Clin Infect Dis 2009, 49(12):1964-1965. author reply 1965.
111. Jeurissen A, Sluyts I, Rutsaert R: A higher dose of vancomycin in continuous infusion is needed in critically ill patients. Int J Antimicrob Agents 2011, 37(1):75-77.
112. De Waele JJ, Danneels I, Depuydt P, Decruyenaere J, Bourgeois M, Hoste E: Factors associated with inadequate early vancomycin levels in critically ill patients treated with continuous infusion. Int J Antimicrob Agents 2013, 41(5):434-438.
113. Saugel B, Nowack MC, Hapfelmeier A, Umgelter A, Schultheiss C, Thies P, Phillip V, Eyer F, Schmid RM, Huber W: Continuous intravenous administration of vancomycin in medical intensive care unit patients. J Crit Care 2013, 28(1):9-13.
114. Ampe E, Delaere B, Hecq JD, Tulkens PM, Glupczynski Y: Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects. Int J Antimicrob Agents 2013, 41(5):439-446.
115. Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N: Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 2012, 67(1):17-24.
116. Stalker DJ, Jungbluth GL: Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003, 42(13):1129-1140.
117. Tsuji Y, Hiraki Y, Mizoguchi A, Hayashi W, Kamohara R, Kamimura H, Karube Y: Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J Infect Chemother 2008, 14(2):156-160.
118. Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Kobayashi T, Sadoh S, Morita K, Kamimura H, Karube Y: Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother 2011, 17(1):70-75.
119. Matsumoto K, Takeshita A, Ikawa K, Shigemi A, Yaji K, Shimodozono Y, Morikawa N, Takeda Y, Yamada K: Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents 2010, 36(2):179-181.
120. Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, Suzuki H, Yata N, Yotsuyanagi H, Moriya K: High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother 2013, 68(9):2128-2133.
121. Sousa R, Lopez R, Martinez-Pastor JC, Cervera C, Bori G, Garcia-Ramiro S, Mensa J, Soriano A: Usefulness of monitoring linezolid trough serum concentration in prolonged treatments. Rev Esp Quimioter 2011, 24(3):151-153.
122. Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, Viale P: Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 2010, 54(11):4605-4610.
123. Hallam MJ, Allen JM, James SE, Donaldson PM, Davies JG, Hanlon GW, Dheansa BS: Potential subtherapeutic linezolid and meropenem antibiotic concentrations in a patient with severe burns and sepsis. J Burn Care Res 2010, 31(1):207-209.
124. Lovering AM, Le Floch R, Hovsepian L, Stephanazzi J, Bret P, Birraux G, Vinsonneau C: Pharmacokinetic evaluation of linezolid in patients with major thermal injuries. J Antimicrob Chemother 2009, 63(3):553-559.
125. Pea F, Scudeller L, Lugano M, Baccarani U, Pavan F, Tavio M, Furlanut M, Rocca GD, Bresadola F, Viale P: Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin Infect Dis 2006, 42(3):434-435.
126. Pea F, Viale P, Lugano M, Pavan F, Scudeller L, Della Rocca G, Furlanut M: Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. Am J Kidney Dis 2004, 44(6):1097-1102.
127. Pea F, Cojutti P, Pagotto A, Cristini F, Furlanut M, Viale P: Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy. Antimicrob Agents Chemother 2012, 56(6):3438-3440.
128. Polillo M, Tascini C, Lastella M, Malacarne P, Ciofi L, Viaggi B, Bocci G, Menichetti F, Danesi R, Del Tacca M, Di Paolo A: A rapid high-performance liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma. Ther Drug Monit 2010, 32(2):200-205.
129. Alffenaar JW, Kosterink JG, van Altena R, van der Werf TS, Uges DR, Proost JH: Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit 2010, 32(1):97-101.
130. Cattaneo D, Baldelli S, Conti F, Cozzi V, Clementi E: Determination of linezolid in human plasma by high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit 2010, 32(4):520-524.
131. Baietto L, D'Avolio A, Ariaudo A, Corcione S, Simiele M, Cusato J, Urbino R, Di Perri G, Ranieri VM, De Rosa FG: Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots. J Chromatogr B Analyt Technol Biomed Life Sci 2013, 936:42-47.
132. Vu DH, Bolhuis MS, Koster RA, Greijdanus B, de Lange WC, van Altena R, Brouwers JR, Uges DR, Alffenaar JW: Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2012, 56(11):5758-5763.
133. Bolhuis MS, van Altena R, van Hateren K, de Lange WC, Greijdanus B, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW: Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2013, 57(8):3676-3680.
134. Kontou P, Chatzika K, Pitsiou G, Stanopoulos I, Argyropoulou-Pataka P, Kioumis I: Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease. Antimicrob Agents Chemother 2011, 55(9):4149-4153.
135. Fish DN, Piscitelli SC, Danziger LH: Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 1995, 15(3):279-291.
136. Gasser TC, Ebert SC, Graversen PH, Madsen PO: Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function. Antimicrob Agents Chemother 1987, 31(5):709-712.
137. Pea F, Poz D, Viale P, Pavan F, Furlanut M: Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. J Antimicrob Chemother 2006, 58(2):380-386.
138. Jones EM, McMullin CM, Hedges AJ, Lovering AM, White LO, Reeves DS, MacGowan AP: The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease. J Antimicrob Chemother 1997, 40(1):121-124.
139. Gous A, Lipman J, Scribante J, Tshukutsoane S, Hon H, Pinder M, Mathivha R, Verhoef L, Stass H: Fluid shifts have no influence on ciprofloxacin pharmacokinetics in intensive care patients with intra-abdominal sepsis. Int J Antimicrob Agents 2005, 26(1):50-55.
140. Fish DN, Bainbridge JL, Peloquin CA: Variable disposition of ciprofloxacin in critically ill patients undergoing continuous arteriovenous hemodiafiltration. Pharmacotherapy 1995, 15(2):236-245.
141. Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L, Lipman J, Bellomo R, RENAL Replacement Therapy Study Investigators: Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 2012, 40(5):1523-1528.
142. van Geijlswijk IM, van Zanten AR, van der Meer YG: Reliable new highperformance liquid chromatographic method for the determination of ciprofloxacin in human serum. Ther Drug Monit 2006, 28(2):278-281.
143. Sousa J, Alves G, Campos G, Fortuna A, Falcao A: First liquid chromatography method for the simultaneous determination of levofloxacin, pazufloxacin, gatifloxacin, moxifloxacin and trovafloxacin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2013, 930:104-111.
144. Al-Ghazawi M, AbuRuz S: Determination of ciprofloxacin in dried blood spots for therapeutic drug monitoring. Chromatographia 2010, 71(11/12):999-1005.
145. Sun HW, He P, Lv YK, Liang SX: Effective separation and simultaneous determination of seven fluoroquinolones by capillary electrophoresis with diode-array detector. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 852(1-2):145-151.
146. Zeng H-J, Yang R, Liu B, Lei L-F, Li J-J, Qu L-B: Simple and sensitive determination of sparfloxacin in pharmaceuticals and biological samples by immunoassay. J Pharmaceutical Analysis 2012, 2(3):214-219.
147. Wenisch JM, Meyer B, Fuhrmann V, Saria K, Zuba C, Dittrich P, Thalhammer F: Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. J Antimicrob Chemother 2012, 67(4):977-983.
148. Falcone M, Russo A, Venditti M, Novelli A, Pai MP: Considerations for higher doses of daptomycin in critically ill patients with methicillinresistant Staphylococcus aureus bacteremia. Clin Infect Dis 2013, 57(11):1568-1576.
149. Pea F, Crapis M, Cojutti P, Bassetti M: Daptomycin underexposure in a young intravenous drug user who was affected by life-threatening Staphylococcus aureus-complicated skin and soft tissue infection associated with bacteraemia. Infection 2014, 42(1):207-210.
150. Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL: Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010, 50(12):1568-1574.
151. Falcone M, Russo A, Cassetta MI, Lappa A, Tritapepe L, d'Ettorre G, Fallani S, Novelli A, Venditti M: Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? J Infect Chemother 2013, 19(4):732-739.
152. Safdar N, Andes D, Craig WA: In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004, 48(1):63-68.
153. Bazoti FN, Gikas E, Skoutelis A, Tsarbopoulos A: Development and validation of an ultra performance liquid chromatography-tandem mass spectrometry method for the quantification of daptomycin in human plasma. J Pharm Biomed Anal 2011, 56(1):78-85.
154. Craig WA: Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995, 22(1-2):89-96.
155. Li C, Du X, Kuti JL, Nicolau DP: Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007, 51(5):1725-1730.
156. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ: Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clinical Pharmacokinet 2003, 42(15):1411-1423.
157. Cattaneo D, Orlando G, Cozzi V, Cordier L, Baldelli S, Merli S, Fucile S, Gulisano C, Rizzardini G, Clementi E: Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Agents 2013, 41(6):586-589.
158. Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M: Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 2012, 67(8):2034-2042.
159. Schentag JJ: Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. J Chemother 1999, 11(6):426-439.
160. Zelenitsky SA, Ariano RE: Support for higher ciprofloxacin AUC 24/MIC targets in treating Enterobacteriaceae bloodstream infection. J Antimicrob Chemother 2010, 65(8):1725-1732.
161. Scaglione F: Can PK/PD be used in everyday clinical practice. Int J Antimicrob Agents 2002, 19(4):349-353.
162. Rodvold KA, Neuhauser M: Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 2001, 21(10 Pt 2):233S-252S.
163. Moore RD, Lietman PS, Smith CR: Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987, 155(1):93-99.